文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
文献AI研究员
20分钟写一篇综述，助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型，支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利：
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2025
相似文献
1
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study.
Front Oncol. 2024 May 31;14:1385425. doi: 10.3389/fonc.2024.1385425. eCollection 2024.
2
Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
J Immunother Cancer. 2021 Jan;9(1). doi: 10.1136/jitc-2020-001642.
3
Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
JAMA Netw Open. 2023 Jun 1;6(6):e2319607. doi: 10.1001/jamanetworkopen.2023.19607.
4
Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Cancer Med. 2019 Dec;8(18):7637-7643. doi: 10.1002/cam4.2625. Epub 2019 Nov 2.
5
Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041.
6
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
JAMA Netw Open. 2021 Dec 1;4(12):e2136823. doi: 10.1001/jamanetworkopen.2021.36823.
7
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Eur J Cancer. 2022 May;167:32-41. doi: 10.1016/j.ejca.2022.02.023. Epub 2022 Mar 30.
8
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12.
9
Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Asia Pac J Clin Oncol. 2019 Feb;15(1):26-30. doi: 10.1111/ajco.13100. Epub 2018 Nov 13.
10
Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma: A Meta-Analysis.
JAMA Oncol. 2023 Oct 1;9(10):1441-1446. doi: 10.1001/jamaoncol.2023.3295.
本文引用的文献
1
Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients.
Melanoma Res. 2024 Apr 1;34(2):134-141. doi: 10.1097/CMR.0000000000000945. Epub 2024 Jan 4.
2
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.
Oncologist. 2023 Sep 7;28(9):812-822. doi: 10.1093/oncolo/oyad073.
3
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
J Clin Oncol. 2022 Apr 1;40(10):1068-1080. doi: 10.1200/JCO.21.01701. Epub 2022 Feb 10.
4
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
5
Immune checkpoint inhibitors in melanoma.
Lancet. 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X.
6
Tumor immunogenomic signatures improve a prognostic model of melanoma survival.
J Transl Med. 2021 Feb 17;19(1):78. doi: 10.1186/s12967-021-02738-0.
7
Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018.
Int J Cancer. 2021 Feb 15;148(4):868-875. doi: 10.1002/ijc.33266. Epub 2020 Sep 12.
8
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Ann Oncol. 2020 Nov;31(11):1435-1448. doi: 10.1016/j.annonc.2020.07.004. Epub 2020 Aug 4.
9
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
JAMA Oncol. 2020 Aug 1;6(8):1256-1264. doi: 10.1001/jamaoncol.2020.2288.
10
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
Br J Clin Pharmacol. 2020 Sep;86(9):1736-1752. doi: 10.1111/bcp.14352. Epub 2020 Jun 5.
Zotero 插件